Tachyarrhythmia
23
2
2
16
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
4.3%
1 terminated out of 23 trials
94.1%
+7.6% vs benchmark
9%
2 trials in Phase 3/4
25%
4 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 16 completed trials
Clinical Trials (23)
Lead Evaluation for Defibrillation and Reliability Post Approval Study
Effectiveness of the Eko Digital Stethoscope in Capturing Infant ECGs
BIO|MASTER.CorSky Family Post-market Study for the CorSky Family of ICDs
Lead EvaluAtion for Defibrillation and Reliability (LEADR) / Lead Evaluation for Defibrillation and Reliability in Left Bundle Branch Area Pacing (LEADR LBBAP)
APART: Prevention and Automatic Therapy of Atrial Arrhythmias in Patients With Paroxysmal Supraventricular Tachycardias
Full Automaticity and Remote Follow-up
Post Market Clinical Follow-up Study for the Pamira ICD Lead Family
Master Study of the BIOMONITOR III and Incision and Insertion Tool (FIT OneStep)
Master Study of the Acticor/Rivacor ICDs/CRT-Ds and the Plexa ProMRI S DX Lead
MCG for Localization of Tachyarrhythmia's Origin
Outcome of Induced Atypical Atrial Flutter
Transcutaneous Vagal Nerve Stimulation to Prevent Tachyarrhythmias in Patients Early Following Myocardial Infarction
Temporary Transvenous Pacemaker Placement by Intracavitary Electrocardiogram Monitoring
BIO|CONCEPT.BIOMONITOR III
ProMRI ICD/CRT-D Post Approval Study
Surface ECG Signal Recording for the Implantable Subcutaneous String Defibrillator (ISSD) Detection Algorithm Performance Assessment
Magnetic Resonance (MR) Conditional Tachyarrhythmia Therapy Products Post-approval Study
BIO|MASTER.Ilivia Family / Plexa
Dexmedetomidine and Fentanyl Versus Midazolam and Remifentanil for Sedation in Patients Undergoing Ablation Procedures
BIO.MASTER.BioMonitor 2 Study